Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.4B
55M shares
52-week range
$48.82 – $85.76
83% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
3.0
EV / FCF (TTM)
29.1
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
www.livanova.comNo one on the platform currently holds LIVN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 183,000 | $11.6M |
No one on the platform has traded LIVN yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 10.7% | 8.2% | ||||
| Profit Margin % | -17.5% | -6.5% | -10.9% | |||
| Free Cash Flow Margin % | 12.5% | 7.7% | 3.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +9.7% on the P/E track.
At today's price, your expected annual return is +15.5% on the P/E track.
At today's price, your expected annual return is +20.4% on the P/E track.
Also held through funds
2 more books hold LIVN indirectly · AVUV 0.4% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +10.4% | $4.36 | $4.27–$4.49 | 18.3× | 7 |
| 2027 | $1.6B | +7.2% | $4.68 | $4.53–$4.90 | 17.0× | 7 |
| 2028 | $1.8B | +7.4% | $5.23 | $4.96–$5.74 | 15.2× | 5 |
| 2029 | $2.1B | +20.0% | $7.09 | $6.92–$7.32 | 11.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $1.09 | $1.26 | +15.6% |
| 2026-05-06 | $0.85 | $0.98 | +15.3% |
| 2026-02-25 | $0.80 | $0.86 | +7.5% |
| 2025-11-05 | $0.92 | $1.11 | +20.8% |
| 2025-08-06 | $0.84 | $1.05 | +25.0% |
| 2025-05-07 | $0.75 | $0.88 | +17.3% |
| 2025-02-25 | $0.80 | $0.81 | +1.3% |
| 2024-10-30 | $0.71 |
| $0.90 |
| +26.8% |
| $3.6B |
| — |
| IRONDisc Medicine, Inc. | $67.71 | -1.76% | $2.6B | — |
| LEGNLegend Biotech Corporation | $18.01 | -2.81% | $3.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Top 5 Buys · Sep 15, 2026 11 BUY signals, 2 cleared all quality gates. $ALL $258.48 Stoch 26.9, Stage 2 Uptrend, 10/10 tech, 5/7 fundamentals, RS 71, Accum 27 $LIVN $80.63 Stoch 28.4, Stage 2 Uptrend, 10/10 tech, 4/7 fundamentals, RS 71, Accum 11 $SPY $QQQ $IWM Improving from yesterday's 1 signal. Market finding its footing. Calm this AM. Calm before the, rates, storm? Not financial advice. For informational purposes only.
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-5-livanova-plc-stock/ $LIVN LivaNova Earnings Transcript
View on StockTwits ↗
$LIVN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.98 up 296.00% YoY • Reported revenue of $390.6M up 10.81% YoY • LivaNova now expects full-year 2026 revenue to grow between 8% and 9% on a constant-currency basis and adjusted diluted earnings per share in the range of $4.30 to $4.40.
View on StockTwits ↗
$LIVN Livanova - A medical technology company that sells products for Cardiopulmonary & Neuromodulation. Only 380 watchers on ST. Last ER was a beat. 4.5B MC & smallish float.
View on StockTwits ↗
$LIVN Share Price: $73.35 Contract Selected: Dec 18, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.22 – $21.04 Potential Upside: 74% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$VVOS $LIVN As you can see under the section "Other Players": These are the only companies listed on Nasdaq. LIVN has a market cap of $4B, and VVOS has a market cap of $10M. https://www.marketsandmarkets.com/Market-Reports/united-states-sleep-apnea-devices-market-220821026.html
View on StockTwits ↗
$LIVN Current Stock Price: $70.43 Contracts to trade: $70.0 LIVN May 15 2026 Call Entry: $1.25 Exit: $1.79 ROI: 43% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗
$LIVN reported 0.98 EPS and 263.30 revenue for Q1. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
View on StockTwits ↗$LIVN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.41 up 106.82% YoY • Reported revenue of $362.3M up 14.34% YoY • LivaNova raised its full-year 2026 constant-currency revenue growth guidance to 7.0% to 8.0% and adjusted diluted EPS to $4.20 to $4.30, while maintaining adjusted free cash flow guidance at $160M to $180M.
View on StockTwits ↗Wall St is expecting 0.90 EPS for $LIVN Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$LIVN Current Stock Price: $70.26 Contracts to trade: $70.0 LIVN Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.